Uncategorized

New Releases from NCBI BookshelfVital and Health Statistics. Series 2, Data Evaluation and Methods Research [Internet].Vital and Health Statistics. Series 2, Data Evaluation and Methods Research [Internet].

Studies of new statistical methodology including experimental tests of new survey methods, studies of vital statistics collection methods, new analytical […]

Uncategorized

New Releases from NCBI BookshelfRemdesivir (Veklury): Therapeutic area: COVID-19 in hospitalized patients: Reimbursement Review [Internet].Remdesivir (Veklury): Therapeutic area: COVID-19 in hospitalized patients: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Uncategorized

New Releases from NCBI BookshelfSecukinumab (Cosentyx): Therapeutic area: Hidradenitis suppurativa: Reimbursement Review [Internet].Secukinumab (Cosentyx): Therapeutic area: Hidradenitis suppurativa: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Uncategorized

New Releases from NCBI BookshelfVirtual Mental Health Counselling: Health Systems [Internet].Virtual Mental Health Counselling: Health Systems [Internet].

Leave a Comment / Uncategorized / admin

The rate of mental illnesses, such as major depressive disorder and generalized anxiety disorder, has significantly increased among people aged

Uncategorized

New Releases from NCBI BookshelfOsimertinib (Tagrisso): Therapeutic area: Non–small cell lung cancer: Reimbursement Review [Internet].Osimertinib (Tagrisso): Therapeutic area: Non–small cell lung cancer: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Uncategorized

New Releases from NCBI BookshelfSpesolimab (Spevigo): Indication: For the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: Reimbursement Recommendation [Internet].Spesolimab (Spevigo): Indication: For the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

Canada’s Drug Agency (CDA-AMC) recommends that Spevigo should be reimbursed by public drug plans for the treatment of generalized pustular

Uncategorized

New Releases from NCBI BookshelfCariprazine (Vraylar): Therapeutic area: Schizophrenia: Reimbursement Review [Internet].Cariprazine (Vraylar): Therapeutic area: Schizophrenia: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Uncategorized

New Releases from NCBI BookshelfPembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].Pembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Uncategorized

New Releases from NCBI BookshelfAmivantamab (Rybrevant): Indication: In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations: Reimbursement Recommendation [Internet].Amivantamab (Rybrevant): Indication: In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

Canada’s Drug Agency (CDA-AMC) recommends that Rybrevant should be reimbursed by public drug plans when used in combination with carboplatin

Uncategorized

New Releases from NCBI BookshelfExagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].Exagamglogene Autotemcel (Casgevy): Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

Canada’s Drug Agency (CDA-AMC) recommends that Casgevy be reimbursed by public drug plans for the treatment of sickle cell disease